ITMN-191: CTA submitted

This quarter, InterMune will start a European Phase Ib trial to evaluate a 14-day regimen of ITMN-191 in combination with Pegasys peginterferon alfa-2a and Copegus ribavirin. Roche markets Pegasys a...